Established in Europe in 2009, mAbxience is a multinational group that operates internationally and has a strong presence in major pharmaceutical markets. The company is committed to high-quality products and processes that meet regulatory and technical requirements in all countries where they operate. They currently have two fully developed biosimilars already on the market, with four more in the developmental phase. By developing, manufacturing, and commercializing monoclonal antibodies at facilities in Spain and Argentina, mAbxience is dedicated to contributing to the sustainability of healthcare systems worldwide. As a high-growth international biotechnology company, they specialize in the research, development, manufacture, and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.